Disease: Myelodysplastic myeloproliferative disease
- <em>BRAF</em> mutation in myeloid neoplasm: incidences and clinical outcomes
- A case of sudden hearing loss in a patient with chronic myelomonocytic leukemia
- A novel subclonal rearrangement of the STRN3::PDGFRB gene in de novo acute myeloid leukemia with NPM1 mutation and its leukemogenic effects
- Allogeneic Hematopoietic Cell Transplantation for Juvenile Myelomonocytic Leukemia with a Busulfan, Fludarabine, and Melphalan Regimen: JPLSG JMML-11
- Allogeneic hematopoietic stem cell transplantation for juvenile myelomonocytic leukemia with intestinal Behcet's disease: A case report
- An unusual response to 5-azacitidine by a patient with chronic myelomonocytic leukemia
- Analysis of CSF3R mutations in atypical chronic myeloid leukemia and other myeloid malignancies
- Androgen use in bone marrow failures and myeloid neoplasms: Mechanisms of action and a systematic review of clinical data
- Assessment of a novel NRAS in-frame tandem duplication causing a myelodysplastic/myeloproliferative neoplasm
- Assessment of Ecotropic Viral Integration Site 2B (EVI2B) Gene in Juvenile Myelomonocytic Leukemia and Neurofibromatosis Type 1 NF1 Tumors
- Atypical CML: diagnosis and treatment
- Azacitidine (Vidaza<sup>®</sup>) in Pediatric Patients with Relapsed Advanced MDS and JMML: Results of a Phase I/II Study by the ITCC Consortium and the EWOG-MDS Group (Study ITCC-015)
- BH3 mimetics and azacitidine show synergistic effects on juvenile myelomonocytic leukemia
- Biallelic inactivation of the NF1 tumour suppressor gene in juvenile myelomonocytic leukaemia: Genetic evidence of driver function and implications for diagnostic workup
- Blastic Plasmacytoid Dendritic Cell Neoplasm: A Comprehensive Review of the Disease, Central Nervous System Presentations, and Treatment Strategies
- Bone marrow graft versus peripheral blood graft in haploidentical hematopoietic stem cells transplantation: a retrospective analysis in1344 patients of SFGM-TC registry
- Cabot rings in a cat with myeloproliferative disease
- Cabot rings in chronic myelomonocytic leukemia
- Cerebral localization of chronic myelomonocytic leukemia and improvement with high-dose cytarabine: A case report
- Characteristics and long-term outcome in a large series of chronic myelomonocytic leukaemia patients including 104 formerly referred to as oligomonocytic
- Characteristics, primary treatment, and survival of MDS/MPN with neutrophilia: a population-based study
- Chronic Myelomonocytic Leukemia Patients With Lysozyme Nephropathy and Renal Infiltration Display Markers of Severe Disease
- Chronic Myelomonocytic Leukemia-Associated Immune Thrombocytopenic Purpura: A Report of a Rare Case and a Review of Literature
- Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management
- Chronic neutrophilic leukemia and atypical chronic myeloid leukemia: 2024 update on diagnosis, genetics, risk stratification, and management
- Clinical Efficacy of Hypomethylating Agent Therapy in Patients with Chronic Myelomonocytic Leukemia
- Clinical outcomes of allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia
- Clinical study of the efficacies of ruxolitinib plus low-dose PTCY for acute GVHD prevention after haploidentical transplantation in malignant hematological diseases
- Coincidence of cutaneous blastic plasmacytoid dendritic cell neoplasm and myelodysplastic syndrome derived from clonal hematopoiesis
- Comparing malignant monocytosis across the updated WHO and ICC classifications of 2022
- Comparison of fludarabine-based conditioning regimens in adult cord blood transplantation for myeloid malignancy: A retrospective, registry-based study
- Concurrent chronic myelomonocytic leukemia and gastric carcinoma: a case report and literature review
- Cutaneous involvement in Ph-negative myeloproliferative neoplasms: from extramedullary hematopoiesis to myeloid metastasis with histiocytic differentiation. A systematic review of the literature
- Cytogenetics in the management of myeloproliferative neoplasms, mastocytosis and myelodysplastic/myeloproliferative neoplasms: Guidelines from the Group Francophone de Cytogenetique Hematologique (GFCH)
- Deciphering Acute Myeloid Leukemia Associated Transcription Factors in Human Primary CD34+ Hematopoietic Stem/Progenitor Cells
- Decitabine plus cedazuridine and venetoclax: the promise of an all-oral therapy for patients with myelodysplastic syndromes and chronic myelomonocytic leukaemia
- Deep immunophenotypic analysis of the bone marrow progenitor cells in myelodysplastic syndromes
- Definitions, Biology, and Current Therapeutic Landscape of Myelodysplastic/Myeloproliferative Neoplasms
- Detection of dysplasia in peripheral blood: Proposal of an algorithm to detect myelodysplastic syndromes and chronic myelomonocytic leukemias on a high-speed technical platform using the Sysmex XN analyser
- Discrepant low von Willebrand factor activity results on the ACL TOP analyzer are frequent in unselected patients with myeloproliferative neoplasms and show no correlation with high-molecular-weight multimer loss or bleeding phenotype
- Discrepant low VWF:GPIbR results on the ACL TOP analyser are frequent in unselected patients with myeloproliferative neoplasms, and show no correlation with high molecular weight multimer loss or bleeding phenotype
- EASIX and CPSS Cytogenetics score-based composite risk model for patients with CMML undergoing allogeneic transplant
- Epigenetic vulnerabilities of leukemia harboring inactivating EZH2 mutations
- Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management
- Extreme thrombocytosis with an aggressive evolution harboring a novel variant of calreticulin (CALR) in exon 3
- Fifth Edition of the World Health Classification of Tumors of the Hematopoietic and Lymphoid Tissue: Myeloid Neoplasms
- First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis
- Germline <em>CSF3R</em> Variant in Chronic Myelomonocytic Leukemia: Linking Genetic Predisposition to Uncommon Hemorrhagic Symptoms
- Germline predisposition to myeloid neoplasms: Characteristics and management of high versus variable penetrance disorders
- Hematological Neoplasms with Eosinophilia
- Identifying patients at risk for hereditary myeloid malignancy syndromes incorporating a novel, self-administered questionnaire to an initial screening platform
- IRAK-4 inhibition: emavusertib for the treatment of lymphoid and myeloid malignancies
- JAK2 R683S Mutation Resulting in Dual Diagnoses of Chronic Eosinophilic Leukemia and Myelodysplastic/Myeloproliferative Overlap Syndrome
- KRAS mutations, autoimmunity and female sex in chronic myelomonocytic leukemia
- Long-term remission of infantile Takayasu arteritis associated with germline CBL syndrome after allogeneic hematopoietic stem cell transplantation: A case report and literature review
- Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee
- MDS/CMML from resource-limited region: Characteristics and comparison to tertiary reference European center
- Molecular features of 109 patients with chronic myelomonocytic leukemia in a single center
- Multiparameter prediction of myeloid neoplasia risk
- Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbidities
- Myelodysplastic neoplasms and chronic myelomonocytic leukaemias
- Myeloid madness: assessing diagnostic inconsistency between the new WHO and ICC schemes for myelodysplastic/myeloproliferative neoplasms
- Natural history study of patients with familial platelet disorder with associated myeloid malignancy
- NLRP3 inflammasome activation and symptom burden in KRAS-mutated CMML patients is reverted by IL-1 blocking therapy
- Noonan Syndrome-related Myeloproliferative Disorder Occurring in the Neonatal Period: Case Report and Literature Review
- Omicron related COVID-19 prevention and treatment measures for patients with hematological malignancy and strategies for modifying hematologic treatment regimes
- Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study
- Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study
- Outcomes of intermediate or high-risk CMML patients treated with hypomethylating agents combined with venetoclax: A single center experience
- Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents
- Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes
- Phase to phase: Navigating drug combinations with hypomethylating agents in higher-risk MDS trials for optimal outcomes
- Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia
- Philadelphia chromosome-negative myeloproliferative chronic neoplasms: is clonal hematopoiesis the main determinant of autoimmune and cardio-vascular manifestations?
- Potential value of high-throughput single-cell DNA sequencing of Juvenile myelomonocytic leukemia: report of two cases
- Preclinical characterization and clinical trial of CFI-400945, a polo-like kinase 4 inhibitor, in patients with relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic neoplasms
- Predicting cytopenias, progression, and survival in patients with clonal cytopenia of undetermined significance: a prospective cohort study
- Rare Ring Chromosome [r(15)]: Cytogenetic Abnormality in TP53-Mutated De Novo AML-M4 Masked as Gastrointestinal Bleed With Rapidly Progressing Hyperleukocytosis and Leukostasis
- Real world implementation of flow cytometric monocyte subset partitioning for distinguishing chronic myelomonocytic leukaemia from other causes of monocytosis
- Real-world data of AML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11)
- Real-world data of MDS and CMML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11)
- Recent advances in the application of induced pluripotent stem cell technology to the study of myeloid malignancies
- Recent Advances towards the Understanding of Secondary Acute Myeloid Leukemia Progression
- Recurrent Aortic Thromboembolism Associated With <em>TET2</em> Mutation in Chronic Myelomonocytic Leukemia
- Report on hematopoietic cell transplantations performed in 2018/2019 focusing on the trends of selection of stem cell sources in the Asia-Pacific region: APBMT Activity Survey
- Results from phase 1 of the MANIFEST clinical trial to evaluate the safety and tolerability of pelabresib in patients with myeloid malignancies
- Sex-associated differences in genomic profile of chronic myelomonocytic leukemia involving differential representation of SRSF2 gene mutation
- Should oligomonocytic CMML be classified as an independent disease entity?
- Survival of Patients with Acute Coronary Syndrome and Hematologic Malignancies-A Real-World Analysis
- Sustained Response to Ruxolitinib of Eosinophilia-Associated Myeloproliferative Neoplasm with Translocation t(8;9)(p21;p24)
- Temporal trend in survival for chronic myelomonocytic leukemia in the US: a population-based study
- TET2 somatic copy number alterations and allelic imbalances in chronic myelomonocytic leukemia
- The role of flow cytometry in the classification of myeloid disorders
- Too many white cells-TAM, JMML, or something else?
- Tretinoin Enhances the Effects of Chemotherapy in Juvenile Myelomonocytic Leukemia Using an Ex Vivo Drug Sensitivity Assay
- U2AF1 pathogenic variants in myeloid neoplasms and precursor states: distribution of co-mutations and prognostic heterogeneity
- Validation of a novel algorithm with a high specificity in ruling out MDS
- Validation of the Artificial Intelligence Prognostic Scoring System for Myelodysplastic Syndromes in chronic myelomonocytic leukaemia: A novel approach for improved risk stratification
- What role for somatic mutations in systemic inflammatory and autoimmune diseases associated with myelodysplastic neoplasms and chronic myelomonocytic leukemias?
- When inflammatory stressors dramatically change, disease phenotypes may transform between autoimmune hematopoietic failure and myeloid neoplasms